Semaglutide vs Retatrutide
Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.
Semaglutide and Retatrutide are both glp1 peptides that come up together constantly. This is a side-by-side comparison on the data that actually matters — evidence tier, FDA status, human trials, and how to source each safely — not hype. It is for research and educational purposes only.
Semaglutide vs Retatrutide: side-by-side
| Semaglutide | Retatrutide | |
|---|---|---|
| Evidence tier | Tier 1 | Tier 1 |
| FDA status | FDA Approved | Phase 3 Trials |
| Human RCTs | 10 | 2 |
| Subjects enrolled | 20,000 | 700 |
| Animal studies | 12 | 10 |
| Category | glp1 | glp1 |
| Half-life | Approximately 7 days, enabling once-weekly administration. | Supports once-weekly administration. |
| Community logs | 1 | 0 |
Key differences
Both Semaglutide and Retatrutide sit at the same evidence tier (Tier 1), so neither has a clear edge in how strong its human data is. Semaglutide is FDA approved for specific uses, while Retatrutide is phase 3 trials and treated as a research compound in the US.
Semaglutide has 10 human trials on record (20,000 subjects) versus Retatrutide's 2 (700 subjects). Evidence tiers are a shorthand for how strong that human data is — see our guide to understanding peptide evidence tiers for how to weigh them.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist approved by the FDA (as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management). It is supported by large phase 3 randomized controlled trials, including cardiovascular outcome data. It is a prescription medication; gray-market research-chemical… Full Semaglutide breakdown →
What is Retatrutide?
Retatrutide is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors being developed for obesity and type 2 diabetes. Phase 2 randomized controlled trials reported among the largest weight reductions seen for an incretin-based therapy, and phase 3 trials are underway. It is not FDA-approved and… Full Retatrutide breakdown →
Where to buy Semaglutide or Retatrutide safely
Both are sold by research-chemical suppliers, not pharmacies, so the source matters as much as the compound. Before buying either, vet sellers on third-party lab testing and enforcement history in the ranked directory of trusted peptide sellers — or jump straight to vetted sources for Semaglutide or Retatrutide. PeptidesHub does not sell either compound.
Frequently asked questions
Semaglutide and Retatrutide are both glp1 peptides. Both Semaglutide and Retatrutide sit at the same evidence tier (Tier 1), so neither has a clear edge in how strong its human data is. Semaglutide is FDA approved for specific uses, while Retatrutide is phase 3 trials and treated as a research compound in the US. See each compound's full evidence breakdown for the underlying studies.